Kisqali (
generic name: ribociclib) is a drug used to treat individuals with advanced or metastatic
breast cancer who have hormone receptor positivity (HR-positive) but negative human epidermal growth factor receptor 2 (HER2-negative). Advanced breast cancer occurs when the cancer has progressed to the tissues surrounding the breast. Metastatic breast cancer refers to cancer that has spread to other parts of the body.
Cyclin-dependent kinases (CDKs) enhance cell division and multiplication in both normal and cancer cells. Kisqali acts by inhibiting CDK in cancer cells, thereby reducing cancer growth and preventing it from spreading further. Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative are the two receptor patterns by which Kisqali treats breast cancer.
Dosage
The dose and regimen for Kisqali is set by the prescribing doctor. The usual recommended dosage is 600 mg (3 tablets) daily for 21 days, followed by a seven-day break. This creates a 28-day cycle that is then repeated.
Kisqali can be taken with or without food.
Storage
Store the Kisqali tablet in the original container below 30ºC / 88ºF.
Store this medication away from the reach of infants and children. Please read our friendly tips on handling medicine safely.
This text is for informational purposes only. Please consult a doctor or pharmacist before using any medication.Â
Read the information leaflet that comes with the medication.
Most people who use Kisqali do not experience any negative side effects. Doctors prescribe Kisqali because they assess that the benefits that such treatment yields outweigh any likely unwanted effects.
Some of the common side effects that have been reported include:
- Infections
- Headaches
- Coughing
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Fatigue
- Hair loss (alopecia)
- Rash
Not all side effects are listed here. If these or other unlisted symptoms persist or worsen, consult a healthcare provider or pharmacist.
Kisqali is indicated as the first-line endocrine-based therapy, in conjunction with an aromatase inhibitor, for adults with HR-positive, HER2-negative advanced or metastatic breast cancer.
Alternatively, it can be combined with fulvestrant as the first-line endocrine-based therapy or after the disease progresses on endocrine therapy in men or postmenopausal women.